A Phase I, Parallel, Open-Label, Multicenter, Two Week, Repeat-Dose Study Evaluating Plasma Amprenavir Pharmacokinetics in HIV-1 Infected Adult Subjects With Mild, Moderate or Severe Hepatic Impairment Receiving Fosamprenavir + Ritonavir Compared to Matched Control Subjects With Normal Hepatic Function.

Trial Profile

A Phase I, Parallel, Open-Label, Multicenter, Two Week, Repeat-Dose Study Evaluating Plasma Amprenavir Pharmacokinetics in HIV-1 Infected Adult Subjects With Mild, Moderate or Severe Hepatic Impairment Receiving Fosamprenavir + Ritonavir Compared to Matched Control Subjects With Normal Hepatic Function.

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Dec 2009

At a glance

  • Drugs Fosamprenavir; Ritonavir
  • Indications HIV-1 infections
  • Focus Pharmacokinetics
  • Most Recent Events

    • 01 Dec 2009 Results published in Antimicrobial Agents and Chemotherapy.
    • 14 Oct 2008 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 19 Oct 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top